Xenon Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Xenon Pharmaceuticals's estimated annual revenue is currently $68.8M per year.
- Xenon Pharmaceuticals received $63.0M in venture funding in September 2018.
- Xenon Pharmaceuticals's estimated revenue per employee is $251,250
- Xenon Pharmaceuticals's total funding is $942.6M.
Employee Data
- Xenon Pharmaceuticals has 274 Employees.
- Xenon Pharmaceuticals grew their employee count by 18% last year.
Xenon Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Commercial VP | Reveal Email/Phone |
2 | Sr. VP, Drug Discovery | Reveal Email/Phone |
3 | VP, Clinical Development | Reveal Email/Phone |
4 | SVP, Head Global Pharmacovigilance & Drug Safety | Reveal Email/Phone |
5 | VP Clinical Operations | Reveal Email/Phone |
6 | VP, Product Development & Operations | Reveal Email/Phone |
7 | VP, Biology | Reveal Email/Phone |
8 | VP, Business Development | Reveal Email/Phone |
9 | SVP | Reveal Email/Phone |
10 | VP, Trial Operations | Reveal Email/Phone |
Xenon Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $33.4M | 166 | -10% | N/A | N/A |
#2 | $68.8M | 274 | 18% | $942.6M | N/A |
#3 | $23.5M | 117 | 0% | N/A | N/A |
#4 | $1.6M | 16 | 45% | $3.7M | N/A |
#5 | $0.7M | 7 | 0% | N/A | N/A |
#6 | $1.5M | 15 | 15% | N/A | N/A |
#7 | $1.4M | 14 | 17% | N/A | N/A |
#8 | $0.7M | 7 | -12% | N/A | N/A |
#9 | $17.7M | 88 | 24% | N/A | N/A |
#10 | $4.6M | 23 | -56% | N/A | N/A |
What Is Xenon Pharmaceuticals?
XENON® (NASDAQ: XENE) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. We apply our expertise to predict which phenotypes are caused by single-gene defects. By identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. Given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
$942.6M
Total Funding
274
Number of Employees
$68.8M
Revenue (est)
18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Xenon Pharmaceuticals News
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Rating) - Equities research analysts at SVB Leerink boosted their Q2 2022 earnings per share...
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of Buy by Analysts. Posted by admin on Apr 22nd, 2022.
BURNABY, British Columbia, April 25, 2022 (GLOBE NEWSWIRE) Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical...
BURNABY, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 10,000,000 common shares, which includes 1,525,423 shares sol ...
BURNABY, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 10,000,000 common shares, which includes 1,525,423 shares sol ...
Other Companies in Burnaby
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $110.3M | 284 | 1% | N/A |
#2 | $63.1M | 284 | 3% | N/A |
#3 | $15M | 287 | N/A | N/A |
#4 | $77.2M | 293 | 40% | $156M |
#5 | $72.1M | 298 | -25% | N/A |
Xenon Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-09-21 | $63.0M | Undisclosed | Jefferies LLC | Article |